Neuropsychology of treatment-resistant schizophrenia

Neil D. Woodward*, Herbert Y. Meltzer

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Scopus citations


Neuropsychological functioning is moderately to severely impaired in nearly all patients with schizophrenia. As cognitive function is highly independent of positive symptoms - the hallmark of treatment-resistant schizophrenia - the nature and severity of cognitive impairment in patients with the treatment-resistant form of schizophrenia is fairly similar to that in non-treatment-resistant patients. Cognition is a strong predictor of functional dimensions of outcome such as social, educational, and vocational achievement. Consequently, cognitive dysfunction is now recognized as an important treatment target. Atypical antipsychotic drugs have a modest beneficial effect on cognition in schizophrenia, for both treatment-resistant and non-treatment-resistant patients. The effort to develop novel treatments that improve cognition is focused on targeted pharmacologic treatments that augment the effects of antipsychotic agents. The possibility that such drugs will have differential effects on treatment-resistant and non-treatment-resistant patients must be considered. This review summarizes the breadth, consequences, and pharmacological treatment of neuropsychological impairment in schizophrenia. Particular emphasis is placed on findings that are relevant to treatment-resistant schizophrenia.

Original languageEnglish (US)
Title of host publicationAdvances in Biological Psychiatry
EditorsHelio Elkis, Herbert Y. Meltzer
Number of pages19
StatePublished - Dec 1 2010

Publication series

NameAdvances in Biological Psychiatry
ISSN (Print)0378-7354
ISSN (Electronic)1662-2774

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Neuropsychology of treatment-resistant schizophrenia'. Together they form a unique fingerprint.

Cite this